MedPath

Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement

Phase 3
Completed
Conditions
Total Knee Arthroplasty (Replacement)
Interventions
Drug: 4975 - 5 mg
Drug: Placebo Comparator
Drug: 4975, 15 and 5 mg
Registration Number
NCT00681356
Lead Sponsor
Anesiva, Inc.
Brief Summary

Evaluate the efficacy, tolerability, safety, and pharmacokinetics of 4975 in patients undergoing total knee replacement

Detailed Description

The purpose of this study is to evaluate the efficacy, tolerability, safety, and pharmacokinetics of 4975 in patients undergoing primary unilateral total knee arthroplasty

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
214
Inclusion Criteria
  • Male or female aged 18 to 85 years with an American Society of Anesthesiologists (ASA) status of I, II, or III
  • Planning to undergo primary unilateral Total Knee Arthroplasty (TKA)

Key

Exclusion Criteria
  • A body mass index (BMI) greater than 43
  • Known bleeding disorder or is taking agents affecting coagulation preoperatively
  • Use of medications or a medical condition that in the investigator's opinion could adversely impact the patient's participation or safety, conduct of the study, or interfere with the pain assessments
  • Diabetes mellitus with a known HbA1C>9.5 or a history of prolonged uncontrolled diabetes
  • Previous knee arthroplasty (partial or total) of the same knee
  • Participated in another clinical trial within 30 days prior to the planned TKA surgery

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
34975 - 5 mg4975 - truncated for Phase 3
2Placebo ComparatorPlacebo
14975, 15 and 5 mg4975 - 15 mg
Primary Outcome Measures
NameTimeMethod
Numerical Rating Scale (NRS) measures of pain at prespecified timesPrimary endpoint is 2 days (4-48 hours)
Secondary Outcome Measures
NameTimeMethod
Other efficacy parameters, safety and tolerability of 497542 Days or Early Termination

Trial Locations

Locations (24)

Temple University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

Miami Institute for Medical Research

🇺🇸

Miami, Florida, United States

Memorial City Hospital - Memorial Hermann Healthcare System

🇺🇸

Houston, Texas, United States

Alabama Clinical Therapeutics, LLC

🇺🇸

Birmingham, Alabama, United States

Glendale Adventist Medical Center - Lotus Clinical Research

🇺🇸

Glendale, California, United States

University of Miami, Miller School of Medicine

🇺🇸

Miami, Florida, United States

Oregon Health & Science University

🇺🇸

Portland, Oregon, United States

Hellen Keller Hospital

🇺🇸

Sheffield, Alabama, United States

Physicians Clinical Research Corporation

🇺🇸

Laguna Hills, California, United States

Saddleback Memorial Medical Center/Accurate Clinical Trials

🇺🇸

Laguna Hills, California, United States

Webster Orthopeadic Medical Group

🇺🇸

Oakland, California, United States

Springhill Medical Center

🇺🇸

Mobile, Alabama, United States

Visions Clinical Research/Tucson Medical Center

🇺🇸

Tucson, Arizona, United States

UCSF-Mt. Zion Medical Center

🇺🇸

San Francisco, California, United States

Rush University Medical Center

🇺🇸

Chicago, Illinois, United States

Southeastern Clinical Research Consultants

🇺🇸

Orlando, Florida, United States

Ruxton Professional Center - Orthopaedic Associates

🇺🇸

Towson, Maryland, United States

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

Orthopedic Associates of Hartford

🇺🇸

Hartford, Connecticut, United States

Florida Hospital - Florida Research Associates, LLC

🇺🇸

DeLand, Florida, United States

Coastal Medical Research

🇺🇸

Port Orange, Florida, United States

William Beaumont Hospital

🇺🇸

Troy, Michigan, United States

Sewickley Valley Hospital

🇺🇸

Sewickley, Pennsylvania, United States

Presbyterian Hospital of Dallas

🇺🇸

Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath